This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Mitochondrial dysfunction (prevention of HIV transmission)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • in France, a report detailed 8 infants whodeveloped mitochondrial dysfunction following intrauterine and perinatal exposure to zidovudine, with or without lamivudine, following treatment to prevent vertical transmission of HIV. None of the infants were found to be infected with HIV

  • the Committee on Safety of Medicines concluded that there is insufficient data, at present, to establish a causal relationship between mitochondrial dysfunction in infants and exposure to antiretroviral drugs in utero

Long term use of zidovudine is reported to cause clinically significant muscle weakness and myopathy in HIV patients

  • the myopathic symptoms often begin after the first 6 months of therapy and include fatigue, muscle weakness and elevation of muscle enzymes. These symptoms occur in at least 17% of patients and are often reversible when zidovudine therapy is discontinued (2,3)

Reference:

  • Current Problems in Pharmacovigilance (1999), 25, 15.
  • Scruggs ER, Dirks Naylor AJ. Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy. Pharmacology. 2008;82:83-8.
  • Sinnwell TM, Sivakumar K, Soueidan S, Jay C, Frank JA, McLaughlin AC, et al. Metabolic abnormalities in skeletal muscle of patients receiving zidovudine therapy observed by 31P in vivo magnetic resonance spectroscopy. J Clin Invest. 1995;96:126-31.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.